ArtVentive Medical Group, Inc. (OTCBB: AVTD) announced today that the Company is expanding its product portfolio to include a unique and proprietary Catheter-Assisted Endovascular Tumor Treatment (CAETT™) system to deliver drugs and agents for minimally invasive, controlled and localized treatment of tumors.

“Chemoembolization, radioembolization particles, embolization glues and microspheres are currently delivered through a microcatheter and can lead to undesirable systemic effects as a result of traveling beyond the target treatment site,” stated Dr. Leon Rudakov, President and Chief Technology Officer. “US and international patent applications were filed in 2013 for the development of the ArtVentive CAETT™ system which will allow controlled, localized delivery of embolic agents. The CAETT™ system will be submitted for both European and FDA regulatory approval following completion of the Company’s rigorous research and development program.”

“The development of the CAETT™ system is based on the Company’s EOS™ proprietary technology,” stated Jim Graham, Chief Executive Officer, ArtVentive Medical Group. “This extraordinary system provides the foundation to expand the Company’s international market reach beyond the already growing ArtVentive EOS™ occlusion market.”

ArtVentive Medical Group, Inc. is known for its development of the EOS™ (Endoluminal Occlusion System), a self-expandable catheter-based device that facilitates immediate, reliable and permanent occlusion of peripheral body lumens. The Company received the European CE Mark certification in 2013 for the EOS™ and is currently shipping to its expanding European distribution network while laying the foundation for launching into the USA and other international markets during 2014, following regulatory approval.

About ArtVentive Medical Group, Inc.

ArtVentive Medical Group, Inc., with corporate headquarters in Carlsbad, California, is an innovative, multi-faceted medical device company committed to developing, manufacturing and marketing a family of devices globally, featuring the EOS™.

The ArtVentive EOS™ is catheter-based and self-expandable and facilitates permanent or temporary occlusion of peripheral body lumens, a cavity found within the vascular system and organ network within the body. The EOS™ will serve in many cases as a safe and reliable alternative to major surgery. This technological innovation is bringing the current interventional, image-guided techniques to a new level of sophistication, resolving significant, unaddressed health issues.

The ArtVentive EOS™ targets the global market in several major clinical areas, including peripheral, neurological vascular, women’s health (minimally invasive contraceptive and birth control), interventional cardiology, pulmonary and interventional oncology.

More information about the Company can be found at www.artventivemedical.com.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements relate to the Company’s current expectations, beliefs, projections and similar expressions concerning matters that are not historical facts and are not guarantees of future performance. Forward-looking statements involve uncertainties, risks, assumptions and contingencies, many of which are outside the Company’s control and which cause actual results to differ materially from those described in or implied by any forward-looking statement. All forward-looking statements are based on currently available information and speak only as of the date on which they are made. The Company assumes no obligation to update any forward-looking statement made in this news release that becomes untrue because of subsequent events, new information or otherwise, except to the extent it is required to do so in connection with its ongoing requirements under federal securities laws. For a further discussion of these and other factors that could cause the Company’s future results to differ materially from any forward-looking statements, see the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission.